Results 101 to 110 of about 277,103 (274)

Structural and biochemical insights into the thermostable esterase Ta0887 from Thermoplasma acidophilum

FEBS Open Bio, EarlyView.
In this study, a novel esterase from the thermoacidophilic archaeon Thermoplasma acidophilum was biochemically and structurally characterized. Our results demonstrate that Ta0887 is a highly thermostable esterase that preferentially hydrolyzes p‐nitrophenyl hexanoate and possesses an α‐helical cap domain that likely contributes to its substrate ...
Alejandro Delgado‐Rey, Miriam Livier Llamas‐García, Gabriela M. Montero‐Morán, Leticia Santos, Samuel Lara‐González   +4 more
wiley   +1 more source

Surrogate endpoints [PDF]

British Journal of Cancer, 1993
openaire   +2 more sources

Threonine 348 regulates the subcellular localization of PTEN

FEBS Open Bio, EarlyView.
Thr348 in the C2 domain is a key contributor to PTEN subcellular localization. The PTEN350 fragment and PTENA4 accumulated in the nucleus, whereas PTENK13R,A4 predominantly localized to the plasma membrane. In contrast, substitution of Thr348 with Asp (T348D) disrupted these characteristic localization patterns, resulting in predominant cytoplasmic ...
Takashi Kato, Suzu Tanaka, Miyu Ohashi
wiley   +1 more source

Special Issue Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma [PDF]

, 2020
With the recent progress in imaging technologies for assessment of structural damage in glaucoma, a debate has emerged on whether these measurements can be used as valid surrogate endpoints in clinical trials evaluating new therapies for the disease.
Felipe A Medeiros
core  

Analysis of effectiveness criteria in pharmacoeconomic studies of hypoglycemic drugs proposed for inclusion into the essential drug list in 2014-2016 in Russia

Качественная клиническая практика, 2018
Rationale. There is a certain variability of endpoints in diabetes pharmacoeconomic research in Russia. It makes difficult to compare the economical effectiveness of hypoglycemic drugs. Aim.
A. A. Mosikyan, A. A. Kurylev, A. S. Kolbin   +2 more
doaj  

Salmonella enterica serovar typhi limits the potency of typhoid toxin and ADP‐ribosylating toxin AB to establish a persistent infection

FEBS Open Bio, EarlyView.
The two catalytic subunits of typhoid toxin dissociate from the holotoxin in the ER of an intoxicated cell, but only CdtB exits the ER to generate immunosuppressive effects. PltA is retained in the ER and sequestered from its cytosolic target, thus allowing the anti‐inflammatory effects of CdtB to promote intestinal colonization.
Maria C. Zabala‐Rodriguez, Juliette K. Tinker, Teresa Frisan, Taj Azarian, Ken Teter   +4 more
wiley   +1 more source

Question: When can surrogate endpoints be used?

, 2014
Statements on when surrogate endpoints can be used in drug marketing authorization, provided that a post-marketing study with hard outcomes will be conducted.
Bauke Schievink (636498), Hubert Leufkens (636499), Hiddo Lambers Heerspink (303367), Jarno Hoekman (303365), Dick De Zeeuw (5660761)   +4 more
core   +1 more source

The C‐terminal truncated splicing variant of NK1R negatively modulates substance P‐stimulated NK1R signaling

FEBS Open Bio, EarlyView.
The neurokinin 1 receptor exists as full‐length (NK1L) and C‐terminally truncated (NK1S) splice variants. We show that NK1S heterodimerizes with NK1L, impairing Gαq coupling and Ca2+ mobilization while enhancing β‐arrestin1 recruitment. NK1S suppresses substance P‐driven gene expression and cell migration, revealing NK1S as an endogenous biased ...
Lan Phuong Nguyen, Duc Trung Nguyen, Minyoung Cho, Jihun Kim, Soyeon In, Thai Uy Nguyen, Sunghoon Hurh, Beom Jin Park, Jong‐Ik Hwang   +8 more
wiley   +1 more source

Ultrasound and radiology surrogate endpoints in pharmacological studies

, 2012
Cardiovascular studies investigating therapeutic intervention with clinical endpoints are costly due to the need for considerable duration and large number of patients, or both.
Barrero, AA, deGroot, E., Agewall, S,, Badano, LP, J. L. Zamorano, Marcos-Alberca, P, S. Agewall, L. P. Badano, deGroot, E, Agewall, S., E. deGroot, Marcos-Alberca, P., Badano, L. P., Perrone-Filardi, P., A. A. Barrero, Zamorano, J. L., Zamorano, JL, Barrero, A. A., Perrone-Filardi, P, P. Marcos Alberca, PERRONE FILARDI, PASQUALE   +20 more
core   +1 more source

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations

ESMO Gastrointestinal Oncology
Background: The BRAF V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy.
J. Ros, V. Navarro, G. Villacampa, I. Baraibar, F. Salvà, M. Rodriguez, C. Vaghi, A. Garcia, A. Alcaraz, J. Tabernero, E. Élez, R. Dienstmann   +11 more
doaj   +1 more source